Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
987actual
Sites
207
Countries
Argentina, Austria, Brazil +20
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2017-03-27 | actual | When the study began enrolling |
| Primary completion | 2020-01-27 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2017-02-06 | estimated | When this record first appeared on the registry |
| Results posted | 2021-03-04 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-07-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Small Cell Lung Carcinoma Extensive Disease
Interventions
- Drug: Durvalumab
- Drug: Tremelimumab
- Drug: Carboplatin
- Drug: Cisplatin
- Drug: Etoposide
Primary outcomes
what the primary-completion date above is the date OFOverall Survival (OS) in the Global Cohort; Assessed at Global Cohort Interim Analysis; D + EP Compared With EP
measured From baseline until death due to any cause. Assessed until global cohort interim analysis DCO (maximum of approximately 23 months).
OS in the Global Cohort; Assessed at Global Cohort Final Analysis; D + EP Compared With EP and D + T + EP Compared With EP
measured From baseline until death due to any cause. Assessed until global cohort final analysis DCO (maximum of approximately 33 months).
OS in the China Cohort; Assessed at China Cohort First Analysis; D + EP Compared With EP
measured From baseline until death due to any cause. Assessed until China cohort first analysis DCO (maximum of approximately 19 months).
OS in the China Cohort; Assessed at China Cohort Second Analysis; D + EP Compared With EP and D + T + EP Compared With EP
measured From baseline until death due to any cause. Assessed until China cohort second analysis DCO (maximum of approximately 29 months).
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2020-01-16 · 2.6 MB · Prot_004.pdf
Statistical Analysis Planposted 2020-10-13 · 2.9 MB · SAP_005.pdf
Publications
- PMID 40331625 — linked by the registry
- PMID 38811992 — linked by the registry
- PMID 33285097 — linked by the registry
- PMID 31590988 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed